SCHEMBL23710339

SCHEMBL23710339

CC(C)(C)OC(=O)c1ccc(CC(CCC(=O)NOCc2ccccc2)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.45
LTA4H P09960 1/20 0.43
SLC7A5 Q01650 1/20 0.40
SYK P43405 1/20 0.40
RAB9A P51151 3/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
EPHX2 P34913 1/20 0.39
PPARG P37231 1/20 0.39
NPC1 O15118 2/20 0.38
LMNA P02545 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ATM Q13315 1/20 0.38
HDAC3 O15379 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26424285 0.92 LTA4H (0.42) FOLH1LTA4HSLC7A5SYKRAB9A
SCHEMBL23704724 0.87 CPA3 (0.49) FOLH1SLC7A5SYKRAB9AKMT2A
SCHEMBL26424302 0.87 SLC7A5 (0.45) SLC7A5SYKRAB9AKMT2AGAA
SCHEMBL26427168 0.87 LTA4H (0.42) FOLH1LTA4HSLC7A5SYKRAB9A
SCHEMBL23704713 0.86 FOLH1 (0.55) FOLH1LTA4HRAB9AEPHX2PPARG
SCHEMBL20179243 0.84 FOLH1 (0.42) FOLH1LTA4HSLC7A5RAB9ANPC1
SCHEMBL23710397 0.80 L3MBTL1 (0.38) SLC7A5SYKRAB9AKMT2ACA2
SCHEMBL14508899 0.79 KMT2A (0.47) FOLH1SLC7A5RAB9AKMT2AGAA
SCHEMBL26424287 0.79 FOLH1 (0.50) FOLH1LTA4HEPHX2PPARGTDP1
SCHEMBL20179186 0.79 SLC7A5 (0.49) FOLH1LTA4HSLC7A5RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4097119-B1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES UNIV JOHNS HOPKINS (US) 2025-05-07 EP disclosed
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2023-04-27 US disclosed
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2023-04-27 US disclosed
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2023-04-27 US disclosed
EP-4097119-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES The Johns Hopkins University (US) 2022-12-07 EP disclosed
WO-2021155167-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES THE JOHNS HOPKINS UNIVERSITY (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) SLC10A2, GPBAR1, NR1H4 FOLH1 828/4885LTA4H 1295/4885SLC7A5 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.